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 NGM282 is a first-in-class, engineered analogue of the
endocrine hormone FGF19.
 NGM282 did not significantly affect alkaline phosphatase
levels in patients with primary sclerosing cholangitis.
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and improved serummarkers of fibrogenesis and liver injury.
 These findings challenge the dogma about what the appro-
priate endpoints should be for trials in PSC.
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Lay summary
We present for the first time, the clinical
and laboratory effects of a first-in-class,
engineered analogue of the endocrine
hormone FGF19 in patients with primary
sclerosing cholangitis (PSC). By incorpo-
rating non-invasive markers of fibrosis,
beyond standard liver injury markers, we
show that NGM282 impacted on fibrosis
turnover and hepatic inflammation with-
out changing alkaline phosphatase. Our
findings demonstrate the complexities of
using highly potent rational agents in PSC,
and furthermore challenge the dogma
about what the appropriate endpoints
should be for trials in PSC.
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Background & Aims: Primary sclerosing cholangitis (PSC) is an
inflammatory, cholestatic and progressively fibrotic liver dis-
ease devoid of effective medical intervention. NGM282, an engi-
neered, non-tumorigenic FGF19 analogue, potently regulates
CYP7A1-mediated bile acid homeostasis. We assessed the activ-
ity and safety of NGM282 in patients with PSC.
Methods: In this double-blind, placebo-controlled phase II trial,
62 patients who had PSC confirmed by cholangiography or
biopsy and an elevated alkaline phosphatase (ALP) >1.5  the
upper limit of normal were randomly assigned 1:1:1 to receive
NGM282 1 mg, 3 mg or placebo once daily for 12 weeks. The
primary outcome was the change in ALP from baseline to week
12. Secondary and exploratory outcomes included changes in
serum biomarkers of bile acid metabolism and fibrosis. Efficacy
analysis was by intention-to-treat.
Results: At 12 weeks, there were no significant differences in
the mean change from baseline in ALP between the NGM282
and placebo groups, and therefore, the primary endpoint was
not met. However, NGM282 significantly reduced levels of
7alpha-hydroxy-4-cholesten-3-one (a marker of hepatic
CYP7A1 activity, LS mean differences 6.2 ng/ml (95% CI
10.7 to 1.7; p = 0.008) and 9.4 ng/ml (14.0 to 4.9;
p <0.001) in the NGM282 1 mg and 3 mg groups, respectively,
compared with placebo) and bile acids. Importantly, fibrosis
biomarkers that predict transplant-free survival, including
Enhanced Liver Fibrosis score and Pro-C3, were significantly
improved following NGM282 treatment. Most adverse events
were mild to moderate in severity, with gastrointestinal symp-
toms more frequent in the NGM282 treatment groups.
Conclusions: In patients with PSC, NGM282 potently inhibited
bile acid synthesis and decreased fibrosis markers, without sig-
nificantly affecting ALP levels.
Lay summary:We present for the first time, the clinical and
laboratory effects of a first-in-class, engineered analogue of
the endocrine hormone FGF19 in patients with primary scleros-
ing cholangitis (PSC). By incorporating non-invasive markers of
fibrosis, beyond standard liver injury markers, we show that
NGM282 impacted on fibrosis turnover and hepatic inflamma-
tion without changing alkaline phosphatase. Our findings
demonstrate the complexities of using highly potent rational
agents in PSC, and furthermore challenge the dogma about what
the appropriate endpoints should be for trials in PSC.
 2018 European Association for the Study of the Liver. Published by
Elsevier B.V. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Introduction
Primary sclerosing cholangitis (PSC) is a chronic liver disease
characterized by strictures of the biliary tree for which there
is presently a dearth of effective medical treatment.1 Of the
histopathological hallmarks of PSC, periductal inflammation
and ‘‘onion skin”-like fibrosis, referring to concentric layers of
collagen fibers circumferential to the cholangiocyte lining of
Journal of Hepatology 2019 vol. 70 j 483–493
Keywords: FGF19; Alkaline phosphatase; Collagen; Fibrogenesis; Enhanced liver
fibrosis; Pro-C3.
Received 30 August 2018; received in revised form 9 October 2018; accepted 29 October
2018; available online 9 November 2018
⇑ Corresponding author. Address: Lily and Terry Horner Chair in Autoimmune Liver
Disease Research, Toronto Centre for Liver Disease, Toronto General Hospital, 9EB-
226, University Health Network, Toronto, ON, Canada.
E-mail address: gideon.hirschfield@uhn.ca (G.M. Hirschfield).
JOURNAL 
OF HEPATOLOGY
Research Article
Cholestasis and Autoimmune Diseases
the bile ducts, characterize a progressive fibrosing cholangiopa-
thy.2 Patients frequently present with concurrent inflammatory
bowel disease (IBD), and are at increased risk of developing
hepatobiliary and colon cancers. More than 50% of patients
need liver transplantation within 10–15 years of symptom
development.1 Biochemically, PSC is characterized by elevated
serum liver tests, and alkaline phosphatase (ALP) levels associ-
ate with future risk of adverse events.
There remains no single specific cause of PSC, and etio-
pathogenesis is believed to encompass genetic, chemical, envi-
ronmental (including microbiome factors) and immunologic
pathways that selectively damage the biliary epithelium.1 A
prevalent ‘‘toxic bile” hypothesis posits that early pathogenesis
of disease results from injury to the integrity of the biliary
epithelium, leading to retention of bile acids and intrahepatic
inflammation and fibrosis. Treatments that ameliorate bile acid
toxicity, or that increase the efflux of bile acids, may slow the
progression of PSC.3 Ursodeoxycholic acid (UDCA), a hydrophilic
bile acid, has been widely prescribed in PSC but without defini-
tive evidence of its clinical benefit, seemingly having choleretic
properties but not anti-fibrotic efficacy.
Fibroblast growth factor 19 (FGF19), an endocrine gastroin-
testinal hormone, controls bile acid metabolism via actions on
CYP7A1, the first and rate-limiting enzyme in the classic path-
way of bile acid synthesis.4,5 Circulating FGF19 concentration
is increased in patients with PSC, further suggesting that
FGF19 may represent an adaptive mechanism in PSC-related
progressive liver diseases.6,7 However, the therapeutic potential
of FGF19 has been hindered by its hepatocarcinogenicity.8
NGM282 (also known as M70), a non-tumorigenic analogue of
FGF19, was designed to retain CYP7A1 suppression to reduce
bile acid-associated biliary injury.9 In NGM282, a 5-amino acid
deletion (P24-S28) coupled with the substitution of 3 amino
acids at critical positions (A30S, G31S, H33L) within the amino
terminus, enable biased FGFR4 signaling so that NGM282 does
not activate signal transducer and activator of transcription 3,
a signaling pathway essential for FGF19-mediated hepatocar-
cinogenesis.10 In animal models of PSC, treatment with
NGM282 resulted in a rapid and robust reduction in ALP, ala-
nine aminotransferase (ALT) and aspartate aminotransferase
(AST) concentrations, as well as a clear improvement in histo-
logical features associated with PSC, including hepatic inflam-
mation and ‘‘onion skin”-like periductal fibrosis.11 NGM282
was safe and well tolerated in healthy volunteers and in
patients with non-alcoholic steatohepatitis (NASH).12,13
We therefore conducted a phase II, multicenter, interna-
tional, randomized, double-blind, placebo-controlled trial to
evaluate the efficacy and safety of NGM282 vs. placebo in adult
patients with PSC.
Patients and methods
Oversight
The trial protocol was approved by the ethics committees and
institutional review boards at each participating site prior to
study initiation. The study was conducted according to the pro-
visions of the Declaration of Helsinki and in compliance with
International Conference on Harmonization Good Clinical Prac-
tice guidelines. All patients provided written informed consent
before participation in the trial. An independent data and safety
monitoring board reviewed safety data. This study was designed
by expert clinicians who had experience in treating PSC in con-
junction with representatives of the sponsor. Data were col-
lected by investigators, and managed, validated and analyzed
by Pharmaceutical Product Development (Morrisville, NC). The
authors had access to the data after unblinding, participated
in data analysis and interpretation, and vouch for the fidelity
of the study to the protocol and the accuracy of the data. All
authors participated in the manuscript development and pro-
vided final approval to submit.
Patients
This multicenter, international trial included male and female
patients, 18 to 75 years of age, who met the diagnostic criteria
for PSC according to the European Association for the Study of
the Liver (EASL) and American Association for the Study of Liver
Diseases (AASLD) guidelines.14,15 Patients were eligible if they
met the following inclusion criteria: 18 to 75 years of age at
the time of screening; confirmed diagnosis of PSC (based on
any 2 of the 3 criteria: abnormal cholangiography consistent
with PSC as measured by magnetic resonance cholangiopancre-
atography, endoscopic retrograde cholangiopancreatography or
percutaneous transhepatic cholangiography; liver biopsy con-
sistent with PSC; historical evidence of elevated ALP); ALP
>1.5  ULN; ALT and AST <5  ULN; bilirubin ≤2.5 mg/dl.
Patients taking UDCA were allowed to enroll if on stable dose
(<27 mg/kg/day) within 2 months of screening. Patients were
also allowed to enroll if they had dominant strictures with no
evidence of clinical concern, IBD with no episode of flare,
autoimmune hepatitis on stable immunosuppressive regimen
with no hepatic flare, compensated cirrhosis or pre-sinusoidal
esophageal varices with no history of bleeding and no other evi-
dence of hepatic decompensation. Exclusion criteria included
clinically significant acute or chronic liver disease of an etiology
other than PSC; evidence of secondary or immunoglobulin G4-
related sclerosing cholangitis per EASL guidelines;14 placement
of a bile duct stent or percutaneous bile duct drain within
3 months of screening; decompensated cirrhosis; and liver
transplantation. A complete list of inclusion and exclusion crite-
ria is provided (Table S1).
Randomization and assignment
Patients were randomly assigned by means of an Interactive
Web Response System in a 1:1:1 ratio to once daily subcuta-
neous NGM282 (NGM Biopharmaceuticals, South San Francisco)
1 mg, NGM282 3 mg or placebo. Randomization was stratified
according to UDCA use (yes or no) to ensure an even distribu-
tion across the treatment arms. The determination of UDCA sta-
tus was based on medical history and concomitant medication
at randomization. NGM282 and placebo were provided as iden-
tical pre-filled syringes in identical containers labelled with
unique code numbers, in keeping with Good Manufacturing
Practice for medicinal products guidelines. A master control list
of the pack identification numbers and treatment was accessible
by the statistician who prepared the randomization schedule.
The list was also provided to the contract research organization
of the emergency un-blinding service. Investigators, staff,
patients, the sponsor, and medical monitors remained blinded
throughout the study period.
Outcomes
The primary outcome measure was the change in ALP from
baseline to end of treatment (EOT) at week 12. Secondary and
exploratory outcomes included changes in 7alpha-hydroxy-4-
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cholesten-3-one (C4, a serum marker of hepatic CYP7A1 activity
indicative of target engagement), bile acids, ALT, AST, and
markers of fibrosis, such as total enhanced liver fibrosis (ELF)
score (including the N-terminal pro-peptide of type III collagen
[PIIINP], the tissue inhibitor of metalloproteinase 1 [TIMP-1]
and hyaluronic acid; measured on ADVIA Centaur CP
Immunoassay System from Siemens) and Pro-C3 (which mea-
sures a neo-epitope of type III collagen during collagen forma-
tion and reflects fibrogenic activity;16 Nordic Bioscience). AEs
were assessed using the Common Terminology Criteria for
Adverse Events v4.03. A complete list of outcome measures is
provided (Table S2).
Procedures
The trial was conducted at 27 sites in Europe and the US and
was designed to have a screening period of 4 weeks, a treatment
period of 12 weeks and a follow-up period of 4 weeks. During
the screening period, patients underwent magnetic resonance
cholangiopancreatography (MRCP) for baseline assessment.
Patients with concomitant IBD also underwent a colonoscopy
procedure if historical reports were obtained 12 months or
more prior to randomization. On day 1, study drug self-
administration instructions and training were provided to
patients, and a weekly study drug kit was dispensed. The first
dose of study drug and doses at weeks 1, 2, 4, 8 and 12 were
self-administered in the clinic; all other doses were adminis-
tered at home. Patients were instructed to inject the study drug
at the same time every morning.
Laboratory and Pro-C3 were assessed at day 1, week 1, 2, 4, 8,
12 and 16 (follow-up). Levels of C4, bile acids, lipids and ELF
scores were measured on day 1 and week 12 (EOT). Adverse
events (AEs) and concomitant medications were evaluated at
each study visit. The schedule for the study visits and data col-
lection is summarized (Table S3).
Statistical analysis
Analyses were conducted on the basis of the intention-to-treat
principle and involved all patients who were randomized to
receive NGM282 or placebo. All tests of effects were conducted
at a 2-sided alpha level of 0.05. A minimal sample size of 60
patients was selected for the pre-study power calculation.
Allowing for a 20% dropout rate, sample size calculations were
based on a minimum of 16 completing patients per group.
The mean change in ALP (primary outcome) from baseline
to week 12 was compared between treatment groups and pla-
cebo using the Wilcoxon Rank Sum test. Continuous outcomes
measured repeatedly over weeks were analyzed with the use
of a mixed-effect model repeated measures (MMRM) analysis
of covariance (ANCOVA), with treatment group, visit, treat-
ment group by visit interaction, UDCA use, treatment group
by UDCA use interaction as classification variables and base-
line value as covariate. For outcomes assessed only at baseline
and at week 12, changes were examined using an ANCOVA
model with treatment group, visit, treatment group by visit
interaction, UDCA use, treatment group by UDCA use interac-
tion as classification variables and baseline value as covariate.
The overall type 1 error was controlled using the step-down
Dunnett multiple testing procedure. Missing data were
imputed using the last post-baseline observation carried for-
ward methodology. SAS version 9.4 (SAS Institute, Cary, NC)
was used to conduct the analyses. Safety and tolerability anal-
yses were conducted in all randomized patients who received
at least 1 dose, full or partial, of study drug and had at least 1
post-dose safety evaluation. All safety endpoints were ana-
lyzed descriptively. The trial was registered with ClinicalTri-
als.gov (NCT02704364).
For further details regarding the methods used, please refer
to trial protocol provided in the supplementary information.
Results
Population
Between February 25, 2016 and February 1, 2017, 95 patients
underwent screening, and 62 eligible patients were randomized
to receive NGM282 1 mg (n = 21), NGM282 3 mg (n = 21) or pla-
cebo (n = 20) (Fig. 1). Baseline demographics and disease char-
acteristics of the three dosing groups were similar (Table 1
and Table S4). A total of 58 patients (95% of the patients in
the NGM282 1 mg group, 90% of those in the NGM282 3 mg
group and 95% of those in the placebo group) completed the
12-week treatment; 4 patients (1 in the NGM282 1 mg group,
2 in the NGM282 3 mg group and 1 in the placebo group) with-
drew from the trial before EOT.
Primary outcome
At 12 weeks, there was no significant difference in ALP with
NGM282 1 mg (least squares [LS] mean difference, 14.0 U/L;
95% CI, 68.0 to 28.0; p = 0.43) and NGM282 3 mg (13.0 U/L,
41.0 to 71.0; p = 0.65) compared with placebo (Fig. 2A and
Table 2). MMRM analyses showed significant decreases in ALP
by the NGM282 1 mg group at week 1, 2 and 4 compared to
baseline; however, the effects were not maintained at week
12 (Fig. S1). Pre-specified subgroup analyses showed a similar
pattern of response in ALP irrespective of concomitant UDCA
use. Similar changes in gamma glutamyltransferase were also
observed (Fig. S2).
Secondary outcomes
Significant reductions in C4 were observed in patients who
received NGM282 (Fig. 2B and Table 2). At 12 weeks, the LS
mean differences in C4 were 6.2 ng/ml (95% CI 10.7 to
1.7; p = 0.008) in the NGM282 1 mg group and 9.4 ng/ml
(95% CI 14.0 to 4.9; p <0.001) in the NGM282 3 mg group
compared with placebo (Table 2). Furthermore, treatment with
NGM282 resulted in decreases in circulating bile acids, and sec-
ondary bile acids in particular (deoxycholic acid, glycodeoxy-
cholic acid, taurodeoxycholic acid, glycolithocholic acid,
taurolithocholic acid), compared with placebo-treated patients
(Fig. 2C and Table 3). Despite significant inhibition of the classic
pathway of de novo bile acid synthesis as evidenced by C4
reduction, no significant changes in serum vitamin D levels,
an indicator of fat-soluble vitamin absorption, were observed
in NGM282-treated individuals (Table S5).
Significant decreases in ALT and AST from baseline were
observed in the NGM282 3 mg group during treatment (Fig. 2-
D-E). The LS mean changes in ALT levels from baseline to week
12 were 8.5 U/L (p = 0.41) and 45.1 U/L (p <0.001) for NGM282
1 mg and 3 mg, respectively, vs. 12.1 U/L (p = 0.25) for placebo.
The LS mean changes in AST levels from baseline to week 12
were 0.2 U/L (p = 0.97) and 30.9 U/L (p <0.001) for NGM282
1 mg and 3 mg, respectively, vs. 13.3 U/L (p = 0.07) for placebo.
Pre-specified subgroup analyses showed similar reductions in
aminotransferases by NGM282 treatment in patients on
concomitant UDCA to those not on UDCA (Figs. S3-4). Post hoc
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33 excluded:
• 10 did not meet ALP criteria
• 4 did not meet ALT, AST or bilirubin criteria
• 1 withdrew consent
• 18 did not meet criteria (other) 
95 patients screened 
62 randomized 
21 assigned to receive NGM282 1 mg 
21 received NGM282 1 mg 
20 assigned to receive placebo 
20 received placebo 
21 assigned to receive NGM282 3 mg 
21 received NGM282 3 mg 
1 discontinued treatment:
• 1 patient choice 
21 included in intention to treat analysis 20 included in intention to treat analysis 
1 discontinued treatment:
• 1 due to AE  
2 discontinued treatment:
• 1 due to AE 
• 1 patient choice 
21 included in intention to treat analysis 
Fig. 1. Trial profile. AE, adverse event; ALP, alkaline phosphatase; ALT, alanine aminotransferase; AST, aspartate aminotransferase.
Table 1. Baseline patient demographics and characteristics.
Placebo (n = 20) NGM282 1 mg (n = 21) NGM282 3 mg (n = 21)
Mean age, years 43.4 ± 12.4 46.0 ± 15.9 40.2 ± 13.0
Male, n (%) 12 (60) 14 (67) 12 (57)
Female, n (%) 8 (40) 7 (33) 9 (43)
Duration of PSC, years 8.1 ± 7.2 7.3 ± 6.1 7.8 ± 7.6
Race, n (%)
Asian 0 1 (5) 0
Black 4 (20) 1 (5) 2 (10)
White 16 (80) 18 (86) 18 (86)
Other 0 1 (5) 1 (5)
Ethnic origin, n (%)
Hispanic/Latino 0 1 (5) 0
UDCA status, n (%)
Concomitant UDCA 13 (65) 13 (62) 13 (62)
No concomitant UDCA 7 (35) 8 (38) 8 (38)
Cholangiography by MRCP or ERCP, n (%)
Large duct PSC 13 (65) 10 (48) 14 (67)
Dominant stricture 5 (25) 2 (10) 3 (14)
Bile acid-related
C4 (ng/ml) 10.5 ± 11.2 12.9 ± 12.8 16.9 ± 18.2
C4 ≤2 ng/ml 5 (25) 4 (19) 4 (19)
Endogenous bile acids (lmol/L) 30.2 ± 33.0 39.1 ± 42.4 20.1 ± 32.0
Endogenous FGF19 (pg/ml) 433.3 ± 339.1 339.7 ± 279.5 305.8 ± 241.1
Serum liver tests
Alkaline phosphatase (U/L) 355.5 ± 137.9 383.2 ± 181.4 353.7 ± 194.0
Alanine aminotransferase (U/L) 90.5 ± 51.8 116.7 ± 70.2 96.1 ± 67.3
Aspartate aminotransferase (U/L) 71.1 ± 36.9 92.6 ± 59.7 70.3 ± 46.4
Total bilirubin (lmol/L) 12.1 ± 6.0 17.9 ± 8.4 10.7 ± 4.3
Fibrosis biomarkers
Pro-C3 (ng/ml) 26.1 ± 16.4 26.7 ± 17.9 24.2 ± 16.7
Pro-C3 ≥ 20 ng/ml 12 (60) 10 (48) 10 (48)
ELF score 10.0 ± 1.4 10.2 ± 1.2 9.5 ± 1.1
Hyaluronic acid (lg/L) 160.8 ± 261.6 203.8 ± 488.7 60.1 ± 60.2
PIIINP (lg/L) 14.2 ± 8.3 13.9 ± 6.3 12.6 ± 4.2
TIMP-1 (lg/L) 338.6 ± 113.6 310.4 ± 74.6 338.4 ± 94.1
ELF >9.8 9 (45) 12 (57) 5 (24)
Shown are mean ± SD or n (%). C4, 7alpha-hydroxy-4-cholesten-3-one; ELF, Enhanced Liver Fibrosis; ERCP, endoscopic retrograde cholangiopancreatography; MRCP,
magnetic resonance cholangiopancreatography; PIIINP, N-terminal propeptide of type III collagen; Pro-C3, neoepitope-specific N-terminal propeptide of type III collagen;
SD, standard deviation; TIMP-1, tissue inhibitor of metalloproteinase 1; UDCA, ursodeoxycholic acid
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analyses revealed that the trend of improvement in liver
enzymes was also observed in patients with suppressed C4
levels at baseline, a population previously linked to worse
outcomes in PSC,7 and in patients with large duct disease or
dominant strictures (Figs. S5–7).
No significant placebo-adjusted changes from baseline to
week 12 were observed for the NGM282 groups in levels of
triglycerides, total cholesterol, HDL cholesterol or LDL choles-
terol (Table 2 and Fig. S8). Changes from baseline to week 12
in additional parameters are summarized in Table 2 and
Table S6.
Serum fibrosis biomarkers
Levels of ELF and Pro-C3, non-invasive fibrosis biomarkers that
predict transplant-free survival in patients with PSC,17–19 were
measured at baseline and after 12 weeks of NGM282 treatment.
Serum ELF test showed a reduction in fibrosis in patients receiv-
ing NGM282 compared with placebo (Fig. 3A and Table 2). The
LS mean changes in ELF from baseline to week 12 were 0.29
(p = 0.028) and 0.37 (p = 0.009) for NGM282 1 mg and 3 mg,
respectively, vs. 0.07 (p = 0.56) for placebo. Improvements in
the individual components of ELF (PIIINP, TIMP-1 and hyaluro-
nic acid) were also observed in patients treated with NGM282
(Fig. S9). Post hoc subgroup analysis revealed that patients with
a higher risk of disease progression (ELF >9.8 at baseline17,18)
had a greater reduction in ELF than patients with a lower dis-
ease risk, with LS mean changes of 0.52 (p <0.001) and
0.58 (p = 0.007) for NGM282 1 mg and 3 mg, respectively, vs.
0.01 (p = 0.97) for placebo (Fig. 3A).
Pro-C3 measures a neo-epitope of type III collagen during
collagen formation and directly reflects fibrogenic activity.16
Reductions in Pro-C3 levels were greater for both NGM282
1 mg and 3 mg groups compared with the placebo group at all
time points during treatment (Fig. 3B-C). At week 12, significant
reductions in Pro-C3 were observed in the NGM282 1 mg group
(LS mean difference, 9.5 ng/ml; 95% CI 17.1 to 2.0; p = 0.01)
and 3 mg group (13.3 ng/ml; 21.0 to 5.6; p = 0.001) com-
pared with the placebo (Table 2). Improvements in Pro-C3 were
most pronounced in patients with advanced fibrogenesis (Pro-
C3 >20 ng/ml) at baseline (Fig. S10).
Safety
A total of 17/21 patients (81%) in the NGM282 1 mg group,
20/21 patients (95%) in the NGM282 3 mg group and 18/20
patients (90%) in the placebo group had adverse events, most
of which were grade 1 and grade 2, during the study period
(Table 4). The most commonly reported adverse events due to
any cause were injection site reaction and diarrhea. Injection
site reaction occurred more frequently in the NGM282 3 mg
group, but appeared to be tolerated over time, as measured by
the local injection site symptom assessment tool (Fig. S11).
Diarrhea was reported in a higher percentage of patients in
the NGM282 groups than placebo, none higher than grade 2
in severity. Assessment of gastrointestinal symptoms by Mayo
Partial IBD score revealed that NGM282 treatment increased
stool frequency, but not rectal bleeding (Fig. S12). A total of 3
patients reported serious adverse events during the trial. One
patient from the NGM282 1 mg group had an elevation in biliru-
bin due to PSC progression and 1 patient from the NGM282
3 mg group had an intervertebral discitis; neither was consid-
ered related to treatment by site investigators. One patient with
concomitant ulcerative colitis in the NGM282 3 mg group had a
bowel obstruction during the follow-up period after EOT, which
resolved in 3 days. This event was considered by the investiga-
tor to be possibly related to the study drug. No adverse events at
or above grade 4 were noted. No deaths occurred during the
course of the study.
None of the patients tested positive for antidrug antibodies
(ADA) at baseline. ADA occurred after baseline during the study
period in 5 of 62 patients, all from the NGM282 3 mg group.
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Fig. 2. Key outcome measures. (A) Serum levels of ALP at baseline and week 12. (B) Serum levels of C4 at baseline and week 12. (C) Serum levels of total
endogenous bile acids at baseline and week 12. (D) Change in ALT from baseline over time. (E) Change in AST from baseline over time. All data are mean ± SEM.
Statistical tests were ANCOVA (panels A-C) or mixed-effect model repeated measures (panels D-E) analyses. *p <0.05, **p <0.01, ***p <0.001. ALP, alkaline
phosphatase; ALT, alanine aminotransferase; AST, aspartate aminotransferase; C4, 7alpha-hydroxy-4-cholesten-3-one; EOT, end of treatment at week 12.
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Table 2. Key outcomes at week 12.
Mean change from baseline to week 12 (SD) LS mean difference (95% CI) (NGM282 vs. Placebo)
Placebo (n = 20) NGM282 1 mg (n = 21) NGM282 3 mg (n = 21) NGM282 1 mg p value NGM282 3 mg p value
ALP
Overall ALP (U/L) 0.6 (79.5) 25.6 (100.3) 9.8 (101.3) 14.0 (68.0, 28.0) 0.43 13.0 (41.0, 71.0) 0.65
Concomitant UDCA 10.2 (73.5) 27.1 (122.8) 6.3 (81.1) 11.0 (44.0, 133.0) 0.78 7.0 (33.0, 60.0) 0.79
No concomitant UDCA 17.1 (93.0) 23.1 (54.0) 34.0 (128.1) 21.0 (119.0, 133.0) 0.68 59.0 (157.0, 225.0) 0.22
7alpha-hydroxy-4-cholesten-3-one (C4)
C4 (ng/ml) 0.5 (11.7) 7.9 (13.3) 14.6 (17.6) 6.2 (10.7, 1.7) 0.008 9.4 (14.0, 4.9) <0.001
Liver function test
ALT (U/L) 4.5 (31.6) 2.8 (62.8) 42.7 (74.5) 20.6 (8.8, 50.0) 0.17 33.0 (66.5, 0.6) 0.06
AST (U/L) 5.3 (25.6) 11.2 (62.2) 24.5 (50.2) 13.0 (7.0, 33.1) 0.20 17.7 (40.3, 5.0) 0.14
GGT (U/L) 18.7 (111.6) 123.8 (263.9) 16.6 (180.0) 152.0 (3.8, 300.2) 0.044 24.9 (156.5, 106.6) 0.70
Total bilirubin (lmol/L) 0.7 (3.2) 10.0 (45.8) 0.5 (3.8) 9.0 (10.2, 28.1) 0.47 0.8 (17.8, 16.2) 0.93
Fibrosis biomarkers
Pro-C3 (ng/ml) 3.5 (8.8) 6.3 (14.3) 9.0 (14.9) 9.5 (17.1, 2.0) 0.014 13.3 (21.0, 5.6) 0.001
ELF score 0.1 (0.5) 0.3 (0.5) 0.3 (0.7) 0.4 (0.7, 0) 0.049 0.4 (0.8, 0.1) 0.023
Hyaluronic acid (lg/L) 12.3 (71.9) 37.6 (129.4) 0.6 (35.2) 14.9 (45.7, 16.0) 0.34 11.7 (43.2, 19.8) 0.46
PIIINP (lg/L) 1.4 (5.3) 3.6 (3.7) 3.9 (3.0) 5.0 (7.7, 2.3) <0.001 5.5 (8.3, 2.8) <0.001
TIMP-1 (lg/L) 2.6 (59.5) 31.1 (43.2) 35.1 (70.2) 35.2 (73.7, 3.3) 0.07 37.7 (76.5, 1.0) 0.06
Lipids
Triglycerides (mmol/L) 0.1 (0.3) 0 (0.6) 0 (0.4) 0 (0.3, 0.2) 0.79 0.2 (0.5, 0.1) 0.21
Cholesterol (mmol/L) 0.2 (0.7) 0.1 (1.0) 0.2 (1.1) 0 (0.7, 0.6) 0.92 0.1 (0.6, 0.8) 0.89
HDL cholesterol (mmol/L) 0.1 (0.2) 0 (0.5) 0 (0.5) 0.1 (0.2, 0.4) 0.59 0.1 (0.2, 0.3) 0.62
LDL cholesterol (mmol/L) 0.1 (0.5) 0.1 (0.8) 0.3 (0.7) 0.1 (0.6, 0.4) 0.73 0.2 (0.4, 0.7) 0.73
The change in ALP (primary outcome) from baseline to week 12 was compared between the treatment groups and placebo using the Wilcoxon Rank Sum test. Change from baseline at week 12 in other measures was compared vs.
placebo using an ANCOVA model with treatment group, visit, treatment group by visit interaction, UDCA use, treatment group by UDCA use interaction as classification variables and baseline value as covariate.
ALP, alkaline phosphatase; ALT, alanine aminotransferase; AST, aspartate aminotransferase; ELF, enhanced liver fibrosis; GGT, gamma-glutamyl transpeptidase; HDL, high-density lipoprotein; LDL, low-density lipoprotein; LS, least
squares mean; PIIINP, N-terminal pro-peptide of type III collagen; Pro-C3, neoepitope-specific N-terminal pro-peptide of type III collagen; TIMP-1, tissue inhibitor of metalloproteinase 1.
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Neutralizing antibodies to FGF19 were not detected in any of
these patients. There was no evidence of clinical safety events
associated with a positive ADA test.
Discussion
PSC is a chronic inflammatory, fibrosing and cholestatic liver
disease, associated with poor outcomes for patients, in which
the need for novel therapies is acute.20 In our randomized,
placebo-controlled, phase II trial of NGM282, drug administra-
tion did not meet the pre-specified primary endpoint of reduc-
tions in the serum marker of cholestasis, ALP, after 12 weeks of
treatment. However, NGM282, a first-in-class FGF19 analogue,
demonstrated potent target engagement, as evidenced by sig-
nificant reductions in C4 and bile acids. The resulting reduction
in levels of aminotransferases and fibrosis biomarkers (ELF and
Pro-C3) nevertheless highlights the compartmentalized poten-
tial efficacy of this new treatment. In keeping with reported effi-
cacy of NGM282 at a similar stage of drug development for
NASH,13 our trial data for the first time in PSC demonstrated a
significant potential anti-fibrotic activity of a therapeutic agent
using a novel biomarker (Pro-C3) in participants. NGM282 was
generally well tolerated at both doses, with most treatment-
related AEs being mild in severity.
The slow rate of disease progression, together with heteroge-
neous pathogenic mechanisms, the lack of defined surrogates of
treatment efficacy and the impracticality of frequent liver biop-
sies (as opposed to blood sampling), have limited the develop-
ment of therapeutics for PSC. At present, there are no
established surrogate endpoints for regulatory approval in
PSC. Several surrogate endpoints, including ALP, were recom-
mended by an international PSC study group.21,22 The observa-
tion that ALP reduction after UDCA treatment can predict
outcomes (liver transplantation and death) in primary biliary
cholangitis (PBC) has inspired studies to assess the association
between ALP reduction and clinical outcome after UDCA treat-
ment in PSC. However, unlike in PBC, ALP has a more unpre-
dictable fluctuating nature in PSC, which may limit the value
of single measurements at any point in time for patient
follow-up or clinical trials.2 Cholangitis, biliary calculi or domi-
nant strictures can cause transient elevations in ALP, generating
difficulty in assessing disease stage and prognosis. Multiple tri-
als of UDCA (13–23 mg/kg) suggested improvements in ALP but
not hard endpoints such as death or liver transplantation.23–25 A
landmark, long-term, randomised, double-blind, placebo-
controlled study of high-dose UDCA (28–30 mg/kg) in 150
patients with PSC was terminated after 6 years due to worsened
outcome (difference in the total number of all endpoints
reached: development of cirrhosis, esophageal varices and
cholangiocarcinoma, listing for liver transplant, and death)
despite a significant reduction in ALP.26–29 The relevance of
ALP for treatment response in PSC is unclear at present.
Diagnosis of PSC depends on identification of fibrotic stric-
tures of the intrahepatic or extrahepatic biliary systems, by
cholangiography or biopsy.20 The pathognomonic lesion in PSC
is an ‘‘onion skin” scar, referring to concentric layer of fibrosis
circumferential to the cholangiocyte lining of the bile ducts.
Despite the association between liver fibrosis stage and
transplant-free survival,30 liver biopsy was not routinely per-
formed due to its invasive nature and inherent sampling vari-
ability in PSC. In contrast to previous trials, we evaluated the
fibrosis biomarkers in addition to the widely used primary end-
point ALP. ELF score, a composite panel of 3 components of
fibrogenesis and matrix remodeling, has been demonstrated to
Table 3. Change in bile acids from baseline to week 12.
Change from baseline to week 12, mean (SD) LS mean difference (95% CI) (NGM282 vs. placebo)
Placebo (n = 20) NGM282
1 mg (n = 21)
NGM282
3 mg (n = 21)
NGM282 1 mg p value NGM282 3 mg p value
Conjugated primary bile acids
GCA (lmol/L) 1.1 (6.8) 10.6 (25.4) 2.9 (10.1) 1.3 (4.8, 2.1) 0.44 2.8 (6.2, 0.6) 0.10
TCA (lmol/L) 0.8 (5.4) 4.5 (15.3) 1.2 (5.0) 0.6 (4.4, 3.1) 0.73 3.0 (6.6, 0.7) 0.11
GCDCA (lmol/L) 3.9 (14.6) 7.6 (14.7) 2.7 (11.3) 3.0 (7.6, 1.6) 0.20 2.6 (7.3, 2.0) 0.26
TCDCA (lmol/L) 1.1 (10.7) 1.1 (5.1) 0.8 (3.7) 0.9 (3.9, 2.1) 0.55 2.4 (5.5, 0.7) 0.12
Conjugated secondary bile acids
GDCA (lmol/L) 0.3 (1.9) 2.2 (3.8) 1.4 (1.9) 1.0 (1.6, 0.3) 0.003 1.2 (1.8, 0.6) <0.001
TDCA (lmol/L) 0.4 (1.4) 0.4 (1.0) 0.4 (0.8) 0.3 (0.9, 0.2) 0.19 0.6 (1.1, 0) 0.033
GLCA (lmol/L) 0 (0.3) 0.1 (0.2) 0.1 (0.3) 0.1 (0.2, 0) 0.036 0.1 (0.2, 0) 0.027
TLCA (lmol/L) 0.03 (0.09) 0.02 (0.04) 0.04 (0.09) 0.05 (0.10, 0.01) 0.024 0.06 (0.11, 0.02) 0.007
Unconjugated primary bile acids
CA (lmol/L) 0.2 (0.6) 0.1 (0.5) 0 (0.2) 0.2 (0.4, 0.1) 0.27 0.1 (0.4, 0.2) 0.51
CDCA (lmol/L) 0.1 (0.8) 0.1 (0.3) 0.1 (0.2) 0.2 (0.5, 0.1) 0.17 0 (0.3, 0.2) 0.78
Unconjugated secondary bile acids
DCA (lmol/L) 0 (0.2) 0.1 (0.1) 0.2 (0.4) 0.1 (0.2, 0.1) <0.001 0.2 (0.2, 0.1) <0.001
LCA (lmol/L) 0 (0.03) 0.02 (0.05) 0.05 (0.15) 0.01 (0.03, 0.01) 0.31 0.02 (0.04, 0.01) 0.16
UDCA and derivatives
GUDCA (lmol/L) 10.0 (39.2) 9.7 (26.8) 1.0 (20.1) 2.2 (18.1, 13.7) 0.78 3.2 (12.9, 19.3) 0.69
TUDCA (lmol/L) 2.0 (7.5) 0.7 (2.8) 0 (1.5) 0.2 (2.1, 1.7) 0.86 0.6 (2.5, 1.4) 0.57
UDCA (lmol/L) 3.0 (10.1) 0.5 (4.1) 1.2 (7.1) 1.1 (2.6, 4.9) 0.55 2.5 (1.2, 6.3) 0.18
Total endogenous bile acids
TEBA (lmol/L) 4.1 (27.4) 19.7 (37.0) 9.6 (31.8) 8.6 (20.8, 3.6) 0.16 12.7 (25.0, 0.5) 0.042
The change in bile acids from baseline to week 12 in bile acids was compared between the treatment groups and placebo using an ANCOVA model with treatment group,
visit, treatment group by visit interaction, UDCA use, treatment group by UDCA use interaction as classification variables and baseline value as covariate.
CA, cholic acid; CDCA, chenocholic acid; DCA, deoxycholic acid; GCA, glycocholic acid; GCDCA, glycochenocholic acid; GDCA, glycodeoxycholic acid; GLCA, glycolithocholic
acid; GUDCA, glycoursodeoxycholic acid; LCA, lithocholic acid; TCA, taurocholic acid; TCDCA, taurochenocholic acid; TDCA, taurodeoxycholic acid; TEBA, total endogenous
bile acids; TLCA, taurolithocholic acid; TUDCA, tauroursodeoxycholic acid; UDCA, ursodeoxycholic acid.
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be a strong predictor of transplant-free survival in patients with
PSC.17,18 In particular, a change in ELF score of 0.19 from base-
line to week 12 has been shown to predict survival free of PSC-
related clinical events, such as ascites, encephalopathy, variceal
hemorrhage, cholangiocarcinomas, jaundice, liver transplant or
death.31 The administered doses of NGM282 reduced ELF
(0.29 and 0.37 from baseline to week 12 for 1 mg and
3 mg, respectively), with the most pronounced improvement
in patients who had an advanced stage of disease (0.52 and
0.58 from baseline to week 12 for 1 mg and 3 mg, respectively,
in patients with baseline ELF >9.8). Serum levels of Pro-C3
reflect fibrogenesis directly by detecting a neo-epitope of
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Fig. 3. Changes in biomarkers of liver fibrosis. (A) Change in ELF from baseline to week 12. Left panel: all patients; middle panel: patients with baseline ELF
≤9.8; right panel: patient with baseline ELF >9.8. (B) Serum concentrations of Pro-C3 over time. (C) Percent change in Pro-C3 from baseline over time. All data
are mean ± s.e.m. Statistical tests were ANCOVA (panel A) or mixed-effect model repeated measures (panels B-C) analyses. *p <0.05, **p <0.01, ***p <0.001. ELF,
Enhanced Liver Fibrosis score; EOT, end of treatment at week 12; FU, follow-up at week 16; Pro-C3, neoepitope-specific N-terminal propeptide of type III
collagen.
Table 4. Summary of adverse events.
Placebo (n = 20) NGM282 1 mg (n = 21) NGM282 3 mg (n = 21)
Adverse event, n (%)
Overall 18 (90) 17 (81) 20 (95)
Grade 1 8 (40) 9 (43) 6 (29)
Grade 2 9 (45) 7 (33) 12 (57)
Grade 3 1 (5) 1 (5) 2 (10)
Grade 4 0 0 0
At least 1 drug-related adverse event, n (%) 13 (65) 13 (62) 16 (76)
At least 1 serious adverse event 0 1# (5) 2^ (10)
At least 1 adverse event leading to study drug discontinuation 0 1# (5) 1* (5)
Most common (>10%) adverse events, n (%)
Injection site reactions 1 (5) 2 (10) 11 (52)
Diarrhea 1 (5) 8 (38) 7 (33)
Abdominal pain 2 (10) 3 (14) 1 (5)
Nausea 4 (20) 2 (10) 3 (14)
Headache 3 (15) 0 (0) 4 (19)
Nasopharyngitis 4 (20) 1 (5) 2 (10)
Frequent bowel movements 0 (0) 3 (14) 3 (14)
Increased appetite 0 (0) 4 (19) 1 (5)
Fatigue 3 (15) 1 (5) 3 (14)
Investigators rated the severity of each adverse event (mild [grade 1], moderate [grade 2], or severe [grade 3]). The events were classified according to Medical Dictionary for
Regulatory Activities (MedDRA) preferred terms. No grade 4 or grade 5 (death) events were reported during the trial period (including follow-up period after end of
treatment). No cases of pancreatitis were reported. #SAE PSC progression (not related). ^SAEs were bowel obstruction (possibly related) and intervertebral discitis (not
related). *Diarrhea. PSC, primary sclerosing cholangitis; SAE, serious adverse event.
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collagen III.16 Pro-C3 has recently been demonstrated to be an
independent predictor of transplant-free survival in PSC, with
an odds ratio of 13.8.19 NGM282 treatment produced rapid,
robust and sustained effect in lowering Pro-C3. The anti-
fibrotic activity of NGM282 in this trial supports the notion that
NGM282 may eliminate toxic effects due to bile acid accumula-
tion in the liver at a stage before the deposition of fibrillary pro-
teins, and is consistent with results from animal models11 and
clinical studies in NASH.13 Overall, the significant reduction in
the levels of fibrotic and inflammation markers that are corre-
lated with disease activity supports a long-held hypothesis that
dysregulated bile acids are a key driver of intrahepatic inflam-
mation and fibrosis, rather than only the bystander of an
autoimmune response. This, in turn, supports the view that a
therapy targeting bile acid metabolism could deliver clinical
benefit without having an early biochemical response in ALP.
Both doses of NGM282 that were administered in this trial
were associated with a high level of target engagement, suffi-
cient to reduce C4 by 61–87%. It is possible that the magnitude
of reduction in C4 was simply insufficient to create a measur-
able effect in change from baseline in ALP, especially when
baseline C4 levels are already suppressed by elevated FGF19
in patients with PSC,3,7 contrasting with observations in animal
models.11 We did note a reduction in ALP within 1 week of
treatment initiation with NGM282 1 mg, which was sustained
through week 4, but diminished in magnitude at week 12. These
findings suggest that the effects of NGM282 on ALP might be
transient and reversed by adaptive mechanisms to re-establish
a new equilibrium. In contrast, the decrease in aminotrans-
ferases is sustained and enduring in patients on NGM282
3 mg, thus the protective effect of NGM282 may be more
parenchymal-focused rather than biliary.
NGM282 was generally well tolerated in the study popula-
tion. Injection site reactions occurred more frequently in the
NGM282 3 mg group, but appeared to be tolerated over time.
Gastrointestinal symptoms were transient and mild to moder-
ate in severity, as observed with NGM282 treatment in patients
with NASH.13 Although elevation of LDL cholesterol due to inhi-
bition of its conversion to bile acid was noted in a previous trial
of NGM282 in patients with NASH,13 we observed no significant
change in LDL cholesterol in patients with PSC. Patients with
PSC frequently develop disabling pruritus and fatigue.
NGM282 did not worsen pruritus or fatigue.
As a master regulator of bile acid metabolism in human
physiology and health, the farnesoid X receptor (FXR)-FGF19
axis is increasingly recognized as an area of great potential for
the treatment of chronic liver disease. A significant component
of FXR-mediated biological activity is attributed to the induc-
tion of endogenous FGF19, a bona fide FXR target gene in the
gut.4 Synthetic activators of FXR have been recently approved
or are currently in clinical development in PBC, PSC and
NASH.32–34 We have recently shown that administration of
NGM282 for 28 days resulted in significant improvements in
ALP and aminotransferase levels compared with placebo in
patients with PBC who had inadequate response to ursodiol.
In contrast with results presented in this report, ALP was signif-
icantly reduced with NGM282 treatment (LS mean differences
of 54 IU/L (p = 0.0149) and 69 U/L (p = 0.0030) for 0.3 mg
and 3 mg, respectively, vs. placebo).35 Whereas ALP is consid-
ered ‘‘reasonably likely” to predict clinical outcome by the Food
and Drug Administration for accelerated approval under Sub-
part H/E for PBC,36 ALP-lowering alone is not regarded as the
primary efficacy outcome for clinical trials in PSC. Nevertheless,
significant decreases in the levels of aminotransferases (ALT and
AST) were observed in patients treated with NGM282 across
PSC, PBC, and NASH populations,13,35 indicating robust activity
of NGM282 against liver injury.
Our trial had several strengths. These include the enrollment
of a broader patient population that is more reflective of
real-world experience. For example, patients with dominant
strictures have significantly worse survival than those
without dominant strictures;37 16% of the patients in this study
have dominant strictures compared with 0% of the patients
in recent PSC trials (obeticholic acid, norUDCA, sim-
tuzumab).33,38,39 Patients with small duct disease, features of
autoimmune hepatitis, and compensated cirrhosis were
included in our trial but were excluded from the other studies.
Importantly, we included fibrosis biomarkers that predict clini-
cal outcome in PSC (ELF) and are novel in monitoring fibrogen-
esis (Pro-C3).
Limitations of this study included a relatively short treat-
ment period and small overall number of patients. The non-
invasive fibrosis biomarkers (Pro-C3 and ELF) used in this study
are only of prognostic value,17,19,40 and have not yet been shown
to change with disease course. Further studies are therefore
needed to examine whether longitudinal change in these mark-
ers correlates with disease course, and their potential as surro-
gate endpoints. Whilst accepting that small duct PSC is an area
of controversy, we elected to include such patients to ensure
that the study, performed in expert centers with experienced
hepatologists, recruited patients for evaluation reflecting the
spectrum of clinical PSC looked after in the community. Addi-
tional limitations include a lack of MRCP at the end of the treat-
ment, although all patients had an MRCP exam during
screening. As cholangiographic changes define the diagnosis of
PSC, evaluation of therapeutics should also focus on the imaging
of bile duct changes, given the recent study showing that MRCP
score correlates with clinical outcome (variceal bleeding,
decompensation, transplant, death) in patients with PSC.41
Additionally, participants did not undergo liver biopsy at the
end of the trial, therefore, it is uncertain whether NGM282-
mediated anti-fibrotic effects can be seen at the histological
level.
The current trial confirms the clinical relevance of the FGF19
pathway in patients with PSC and the concept that it could be
harnessed therapeutically to change the course of the disease.
Longer trials with a larger number of patients are however
needed to better understand the effects of NGM282 therapy in
PSC. Given that liver biopsies are not routinely conducted to
assess disease progression in patients with PSC, future trials
should examine longitudinal change in transient elastography
and MRCP, and correlate with serum markers of fibrosis turn-
over and hepatic inflammation. These studies will have impor-
tant implications as they may demonstrate the complexities of
testing therapeutic agents in PSC and challenge the dogma
about what the appropriate endpoints should be for trials in
PSC.
In conclusion, in patients with PSC, NGM282 demonstrated
significant and robust activities on bile acid metabolism and
anti-fibrotic effects, without reducing ALP. Further trials with
NGM282 in patients with PSC should focus on longer term
administration and an array of biochemical and imaging
endpoints that reflect closer the underlying pro-fibrotic nature
of PSC.
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